RGMa BINDING PROTEIN AND USE THEREOF
AssigneesMitsubishi Tanabe Pharma Corporation, Osaka University, National University Corporation Chiba University
InventorsMotonori HASHIMOTO, Toshihide YAMASHITA
Life of this patent
Estimating the term…
Loading patent…
AssigneesMitsubishi Tanabe Pharma Corporation, Osaka University, National University Corporation Chiba University
InventorsMotonori HASHIMOTO, Toshihide YAMASHITA
Estimating the term…
The present invention aims to obtain an anti-repulsive guidance molecule a (RGMa) antibody having a high binding activity and few side effects which can be used as a medicine for preventing, treating, or preventing the relapse of neurological or immunological diseases. The problem is solved by providing an isolated RGMa binding protein which does not inhibit binding between RGMa and neogenin but neutralizes the neurite outgrowth inhibiting activity of RGMa, preferably by providing an anti-RGMa antibody which has complementarity determining regions having amino acid sequences of SEQ ID NOS: 30-35 or SEQ ID NOS: 36-40 in Sequence Listing, and SFG.
An RGMa-binding protein, which competes with an anti-RGMa antibody, wherein the anti-RGMa antibody has the amino acid sequence of each of the light chain complementarity determining region 1 (LCDR1), the light chain complementarity determining region 2 (LCDR2), the light chain complementarity determining region 3 (LCDR3), the heavy chain complementarity determining region 1 (HCDR1), the heavy chain complementarity determining region 2 (HCDR2) and the heavy chain complementarity determining region 3 (HCDR3) comprises the following:
Dependencies are inferred from the claim text.